NCT00286806View on ClinicalTrials.gov

A Study of Single-Agent AT-101 in Men With Hormone Refractory Prostate Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

December 31, 2005

Primary Completion Date

June 30, 2007

Study Completion Date

June 30, 2007

Conditions
Hormone Refractory Prostate Cancer
Interventions
DRUG

AT-101

Trial Locations (4)

Unknown

Greenbrae

New Haven

Memphis

Madison

Sponsors
All Listed Sponsors
lead

Ascenta Therapeutics

INDUSTRY

NCT00286806 - A Study of Single-Agent AT-101 in Men With Hormone Refractory Prostate Cancer | Biotech Hunter | Biotech Hunter